What is the strongest GLP-1 drug for weight loss?

As of 2026, tirzepatide (branded as Zepbound for weight management) has shown the highest average weight loss in clinical trials — around 20.9% of body weight at the highest dose in the SURMOUNT-1 trial. Retatrutide, a triple-receptor agonist still in late-stage trials, may surpass this. However, individual results vary considerably, so the 'strongest' drug isn't necessarily the best fit for every patient.

Is there a GLP-1 pill instead of an injection?

Yes. Rybelsus (oral semaglutide) is available as a daily tablet for type 2 diabetes. A higher-dose version (25 mg) has been developed to provide weight loss results closer to injectable semaglutide. You need to take it on an empty stomach with no more than 4 ounces of water, then wait at least 30 minutes before eating or taking other medications.

What's the difference between Ozempic and Wegovy?

They contain the same active ingredient — semaglutide — made by the same company (Novo Nordisk). The difference is the approved use and maximum dose. Ozempic is approved for type 2 diabetes (max 2 mg weekly), while Wegovy is approved for weight management (max 2.4 mg weekly). Your doctor will prescribe the one that matches your diagnosis.

How is tirzepatide (Mounjaro/Zepbound) different from semaglutide?

Tirzepatide activates two receptors — GLP-1 and GIP — while semaglutide only activates GLP-1. This dual action appears to produce greater weight loss and blood sugar lowering. In the SURPASS-2 head-to-head trial, tirzepatide outperformed semaglutide 1 mg on both measures. However, semaglutide has more completed cardiovascular outcomes data.

Will insurance cover GLP-1 drugs for weight loss?

Coverage is improving but inconsistent. GLP-1 drugs prescribed for diabetes (Ozempic, Mounjaro, Trulicity) generally have better coverage. Weight management drugs (Wegovy, Zepbound) are increasingly covered, and Medicare Part D began covering certain anti-obesity medications in 2026. Check with your specific plan and ask your doctor's office to do a prior authorization — many people who assume they won't be covered are surprised.

Every GLP-1 Drug Available in 2026: A Complete List

If you've been following the GLP-1 conversation — and honestly, who hasn't at this point — you've probably noticed something: the list of available drugs keeps getting longer. What started as a niche diabetes treatment has turned into one of the most significant pharmaceutical categories of the decade.

But here's the problem. Most "drug list" articles are either hopelessly outdated, written for endocrinologists, or buried in pharma jargon that doesn't help you actually understand what's available. This guide is different. We're going to walk through every GLP-1 and GLP-1-based medication you can actually get prescribed in 2026, in plain language.

What Are GLP-1 Drugs, Quickly?

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally produces after eating. GLP-1 receptor agonists are medications that mimic this hormone, and they do a few important things: they help your pancreas release insulin when blood sugar is high, they slow down stomach emptying (so you feel full longer), and they act on appetite centers in the brain to reduce hunger.

Originally developed for type 2 diabetes, these drugs have since proven remarkably effective for weight management — and research keeps uncovering new benefits, from cardiovascular protection to potential effects on liver disease and kidney function.

The Complete GLP-1 Drug List for 2026

Let's break this down by drug class and individual medication. Some are pure GLP-1 receptor agonists, while newer options target multiple receptors simultaneously.

Pure GLP-1 Receptor Agonists

1. Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is the drug that kicked off the GLP-1 revolution in mainstream culture. Manufactured by Novo Nordisk, it comes in three branded forms:

Ozempic — injectable, FDA-approved for type 2 diabetes. Doses range from 0.25 mg to 2 mg weekly.
Wegovy — injectable, FDA-approved for chronic weight management. Higher dose (up to 2.4 mg weekly) than Ozempic.
Rybelsus — oral tablet form, approved for type 2 diabetes. Available in 3 mg, 7 mg, and 14 mg doses taken daily.

In the landmark STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM 2021). That study fundamentally changed how doctors think about obesity treatment.

2. Liraglutide (Victoza, Saxenda)

Liraglutide was one of the earlier GLP-1 drugs and is also made by Novo Nordisk.

Victoza — daily injection for type 2 diabetes (up to 1.8 mg).
Saxenda — daily injection for weight management (up to 3 mg).

While it's been somewhat overshadowed by semaglutide's stronger weight loss results, liraglutide remains widely prescribed and has robust long-term safety data. The LEADER cardiovascular outcomes trial demonstrated a significant reduction in major adverse cardiovascular events (Marso et al., NEJM 2016).

3. Dulaglutide (Trulicity)

Made by Eli Lilly, Trulicity is a once-weekly injection approved for type 2 diabetes. Doses go up to 4.5 mg. It's one of the most prescribed GLP-1 drugs globally, largely because of its easy-to-use pre-filled pen and established track record.

The REWIND trial showed that dulaglutide reduced cardiovascular events in people with type 2 diabetes, including those without established cardiovascular disease — a finding that expanded how we think about who benefits from these drugs (Gerstein et al., Lancet 2019).

4. Exenatide (Byetta, Bydureon BCise)

Exenatide holds the distinction of being the first GLP-1 receptor agonist approved in the US (back in 2005). Made by AstraZeneca:

Byetta — twice-daily injection.
Bydureon BCise — once-weekly extended-release injection.

Both are approved for type 2 diabetes. The weight loss with exenatide is more modest compared to newer agents, but it remains a viable option, especially for patients who've done well on it.

5. Lixisenatide (Adlyxin)

A once-daily injection from Sanofi, approved for type 2 diabetes. Lixisenatide is a shorter-acting GLP-1 agonist, which means it primarily targets post-meal blood sugar spikes rather than providing 24-hour coverage. It's less commonly prescribed as a standalone but is used in combination therapy.

6. Oral Semaglutide — Higher Dose (Rybelsus 25 mg)

Novo Nordisk has pushed the boundaries of oral GLP-1 therapy. The higher-dose oral semaglutide (25 mg daily) delivers weight loss results closer to what injectable semaglutide achieves — a significant development for patients who prefer pills over needles.

Dual and Multi-Receptor Agonists (The Next Generation)

7. Tirzepatide (Mounjaro, Zepbound)

This is the big one. Tirzepatide, from Eli Lilly, is a dual GIP/GLP-1 receptor agonist — meaning it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

Mounjaro — approved for type 2 diabetes.
Zepbound — approved for chronic weight management.

The weight loss numbers with tirzepatide are staggering. In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost an average of 20.9% of body weight — with over half losing 20% or more (Jastreboff et al., NEJM 2022). That's approaching what was previously only achievable with bariatric surgery.

In head-to-head trials against semaglutide (SURPASS-2), tirzepatide showed superior blood sugar lowering and weight loss at all doses tested (Frías et al., NEJM 2021).

8. CagriSema (Cagrilintide + Semaglutide)

Novo Nordisk's combination of semaglutide with cagrilintide (a long-acting amylin analog). This targets both GLP-1 and amylin pathways. Early trial data has shown impressive weight loss results potentially exceeding what semaglutide alone achieves. It's in late-stage development and expected to be a major player.

9. Survodutide

Boehringer Ingelheim's dual glucagon/GLP-1 receptor agonist. By adding glucagon receptor activation, survodutide may offer enhanced fat burning and energy expenditure on top of the appetite suppression from GLP-1. It's shown particular promise for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) — fatty liver disease.

10. Retatrutide

Eli Lilly's triple agonist — hitting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data showed weight loss of up to 24% of body weight at 48 weeks, which would make it the most potent obesity drug ever tested if phase 3 results hold up. Still in late-stage trials as of 2026.

Combination Products

11. Insulin Degludec + Liraglutide (Xultophy)

A fixed-ratio combination of basal insulin (degludec) and liraglutide in a single daily injection. Approved for type 2 diabetes when either component alone isn't enough.

12. Insulin Glargine + Lixisenatide (Soliqua)

Similar concept — combines basal insulin glargine with lixisenatide. Also approved for type 2 diabetes as a once-daily injection.

How Do These Drugs Compare?

Here's what matters for most people making a decision with their doctor:

For weight loss potency: Tirzepatide (Zepbound/Mounjaro) currently leads, followed closely by high-dose semaglutide (Wegovy). Retatrutide may surpass both once approved.

For diabetes management: Tirzepatide showed the strongest A1C reductions in head-to-head trials, but semaglutide and dulaglutide are both excellent options with extensive real-world data.

For cardiovascular protection: Semaglutide (SELECT trial), liraglutide (LEADER trial), and dulaglutide (REWIND trial) all have completed cardiovascular outcomes trials showing benefit. Tirzepatide's cardiovascular outcomes data is still maturing.

For needle-averse patients: Oral semaglutide (Rybelsus) is the clear choice, though it requires specific dosing instructions (take on an empty stomach, wait 30 minutes before eating).

For convenience: Weekly injections (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon) win over daily options (Victoza, Saxenda, Byetta, Adlyxin).

What About Cost and Insurance?

Let's be honest — this is where it gets painful. Without insurance, most GLP-1 medications cost $800 to $1,300+ per month. Insurance coverage varies wildly:

Diabetes indications (Ozempic, Mounjaro, Trulicity) generally have better insurance coverage.
Weight management indications (Wegovy, Zepbound) are increasingly covered but many plans still exclude them.
Medicare Part D began covering anti-obesity medications for certain patients starting in 2026 — a huge shift.
Manufacturer savings cards can reduce costs significantly for commercially insured patients.

Talk to your doctor and pharmacist about coverage before assuming you can't afford these medications. The landscape is changing fast.

Side Effects Across the Class

GLP-1 drugs share a similar side effect profile, primarily gastrointestinal:

Nausea — the most common, especially during dose escalation. Usually improves over weeks.
Vomiting and diarrhea — less common but possible.
Constipation — reported with several GLP-1 drugs.
Injection site reactions — generally mild.

Serious but rare risks include pancreatitis and, in animal studies, thyroid C-cell tumors (leading to a boxed warning about medullary thyroid carcinoma risk). Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.

The slow dose-escalation schedules built into most GLP-1 drugs exist specifically to minimize GI side effects. Don't skip the titration — it matters.

Practical Takeaways

There's no single "best" GLP-1 drug. The right choice depends on your diagnosis (diabetes vs. weight management), insurance coverage, side effect tolerance, and preferences (injection vs. oral).
The field is evolving fast. Dual and triple agonists like tirzepatide and retatrutide represent a genuine leap forward. If you started a GLP-1 drug two years ago, it's worth asking your doctor whether newer options might work better.
Don't compare yourself to clinical trial averages. Individual responses vary significantly. Some people lose 25% of their body weight; others lose 8%. Both are meaningful.
These are long-term medications. Research consistently shows that weight tends to return after stopping GLP-1 drugs. Think of them like blood pressure medication — managing a chronic condition, not a short-term fix.
Lifestyle still matters. GLP-1 drugs work best when combined with dietary changes and physical activity. They're a powerful tool, not a replacement for healthy habits.

What's Coming Next?

The GLP-1 pipeline is packed. Beyond retatrutide and CagriSema, companies are developing oral versions of tirzepatide, longer-acting formulations, and combinations targeting entirely new pathways. Amgen's MariTide (a GLP-1/GIPR antibody) uses a fundamentally different approach — monthly dosing instead of weekly.

We're also seeing expansion into new conditions: MASH/fatty liver disease, sleep apnea, chronic kidney disease, and even addiction. The GLP-1 story is far from over.

Last updated: April 2026. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or changing medications.